Table 2.

Variance in the thickness of retinal nerve fiber layer (μm) in the group administered intravitreal ranibizumab injection.

	Treated eye	Fellow eye	p valuea
Global RNFL
Baseline	101.03 ± 15.07	98.90 ± 14.33	0.608
Third month	99.24 ± 15.54	98.89 ± 15.34	0.967
Sixth month	98.14 ± 16.29	97.52 ± 16.53	0.973
Twelfth month	99.32 ± 14.07	98.00 ± 16.16	0.967
p valueb	0.038*	0.812
Superior temporal sector RNFL
Baseline	133.86 ± 25.82	133.76 ± 30.54	0.785
Third month	134.83 ± 29.89	134.70 ± 32.30	0.812
Sixth month	138.21 ± 30.28	133.15 ± 34.58	0.637
Twelfth month	135.60 ± 26.48	134.61 ± 34.46	0.710
p valueb	0.344	0.845
Temporal sector RNFL
Baseline	77.76 ± 18.80	71.41 ± 14.40	0.135
Third month	73.45 ± 17.12	72.00 ± 14.93	0.634
Sixth month	73.32 ± 16.56	70.89 ± 14.34	0.755
Twelfth month	74.24 ± 18.32	71.35 ± 15.16	0.556
p valueb	0.058	0.614
Inferior temporal sector RNFL
Baseline	150.21 ± 26.55	145.48 ± 26.35	0.549
Third month	147.21 ± 26.72	147.93 ± 27.77	0.844
Sixth month	146.64 ± 24.92	147.63 ± 28.82	0.698
Twelfth month	149.96 ± 23.51	144.87 ± 28.32	0.650
p valueb	0.435	0.476
Inferior nasal sector RNFL
Baseline	111.79 ± 21.98	110.69 ± 21.88	0.797
Third month	110.90 ± 22.58	110.19 ± 24.09	0.793
Sixth month	108.82 ± 22.37	110.07 ± 22.98	0.794
Twelfth month	109.72 ± 20.95	110.39 ± 23.04	0.975
p valueb	0.939	0.489
Nasal sector RNFL
Baseline	70.69 ± 15.82	71.17 ± 12.16	0.613
Third month	70.45 ± 16.34	69.56 ± 12.11	0.967
Sixth month	71.32 ± 15.25	68.00 ± 13.90	0.464
Twelfth month	68.96 ± 15.76	68.83 ± 12.15	0.680
p valueb	0.753	0.476
Superior nasal sector RNFL
Baseline	115.17 ± 22.15	116.07 ± 28.01	0.635
Third month	114.34 ± 21.97	114.26 ± 28.79	0.799
Sixth month	114.21 ± 21.25	113.52 ± 30.42	0.973
Twelfth month	112.96 ± 22.69	112.22 ± 30.82	0.926
p valueb	0.123	0.305

RNFL retinal nerve fiber layer.

^aComparison between the treated and fellow eyes in each period (Mann–Whitney U-test).

^bComparison between the baseline and twelfth month for each value (Wilcoxon signed-rank test).

* p <.05.